The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Exciting advances in the MPN field: novel JAK inhibitors, targeting mutant CALR & more
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of exciting advances in myeloproliferative neoplasms (MPNs), including the development of novel JAK inhibitors, CALR-targeting approaches, and the emerging hepcidin mimetics and modulators. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
